Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013;18(8):e28.
doi: 10.1634/theoncologist.2013-0221.

IMPACT Study: Targeted Prostate Cancer Screening

Christos Mikropoulos, Rosalind A Eeles
Comment

IMPACT Study: Targeted Prostate Cancer Screening

Christos Mikropoulos et al. Oncologist. 2013.

Abstract

This letter to the editor clarifies the difference between two similarly named studies and expands on the progress of one—the Identification of Men with a Genetic Predisposition to Prostate Cancer study (IMPACT): Targeted screening in BRCA1/2 mutation carriers and controls.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Comment on

References

    1. Merseburger AS, Bellmunt J, Jenkins C, et al. Perspectives on treatment of metastatic castration-resistant prostate cancer. The Oncologist. 2013;18:558–567. - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. - PubMed
    1. IMPACT (The Identification of Men with a Genetic Predisposition to Prostate Cancer Study. Targeted screening in BRCA1/2 mutation carriers and controls) Available at www.impact-study.co.uk.
    1. Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int. 2011;107:28–39. - PMC - PubMed
    1. Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:929–935. - PubMed

MeSH terms

Substances